P&T Sessions
Immunology Biosimilars: Webcast
MMIT recently held a syndicated 90-minute Webcast including the key faculty from our P&T panel, alongside key physician experts.
MMIT recently held a syndicated 90-minute Webcast including the key faculty from our P&T panel, alongside key physician experts.
MMIT recently held a syndicated, simulated P&T session focused on the approvals of mirikizumab and filgotinib, and the launch of Amjevita (biosimilar Humira).
P&T Session Immunology Biosimilars: MMIT recently held a syndicated 90-minute Webcast including the key faculty from our P&T panel, alongside key physician experts.
P&T Session Immunology Biosimilars: MMIT recently held a syndicated 90-minute Webcast including the key faculty from our P&T panel, alongside key physician experts.
P&T Session Immunology Biosimilars: MMIT recently held a syndicated 90-minute Webcast including the key faculty from our P&T panel, alongside key physician experts.
P&T Session Immunology Biosimilars: MMIT recently held a syndicated 90-minute Webcast including the key faculty from our P&T panel, alongside key physician experts.
P&T Session Ulcerative Colitis: MMIT recently held a syndicated, simulated P&T session focused on the approvals of mirikizumab and filgotinib, and the launch of Amjevita (biosimilar Humira).
P&T Session Ulcerative Colitis: MMIT recently held a syndicated, simulated P&T session focused on the approvals of mirikizumab and filgotinib, and the launch of Amjevita (biosimilar Humira).
P&T Session Ulcerative Colitis: MMIT recently held a syndicated, simulated P&T session focused on the approvals of mirikizumab and filgotinib, and the launch of Amjevita (biosimilar Humira).
P&T Session Ulcerative Colitis: MMIT recently held a syndicated, simulated P&T session focused on the approvals of mirikizumab and filgotinib, and the launch of Amjevita (biosimilar Humira).
MMIT recently held a syndicated simulated P&T session focused on the approvals of ruxolitinib cream (Opzelura), lebrikizumab, and tralokinumab for atopic dermatitis.
P&T Session Atopic Dermatitis: MMIT recently held a syndicated simulated P&T session focused on the approvals of ruxolitinib cream (Opzelura), lebrikizumab, and tralokinumab for atopic dermatitis.
P&T Session Atopic Dermatitis: MMIT recently held a syndicated simulated P&T session focused on the approvals of ruxolitinib cream (Opzelura), lebrikizumab, and tralokinumab for atopic dermatitis.
P&T Session Atopic Dermatitis: MMIT recently held a syndicated simulated P&T session focused on the approvals of ruxolitinib cream (Opzelura), lebrikizumab, and tralokinumab for atopic dermatitis.
P&T Session Atopic Dermatitis: MMIT recently held a syndicated simulated P&T session focused on the approvals of ruxolitinib cream (Opzelura), lebrikizumab, and tralokinumab for atopic dermatitis.
P&T Session Atopic Dermatitis: MMIT recently held a syndicated simulated P&T session focused on the approvals of ruxolitinib cream (Opzelura), lebrikizumab, and tralokinumab for atopic dermatitis.
MMIT’s P&T Persectives on Neutropenia reviewed Rolontis® (eflapegrastim), a new long-acting rhG-CSF therapy for patients with chemotherapy induced neutropenia.
MMIT’s P&T Persectives on Neutropenia reviewed Rolontis® (eflapegrastim), a new long-acting rhG-CSF therapy for patients with chemotherapy induced neutropenia.
MMIT’s P&T Persectives on Neutropenia reviewed Rolontis® (eflapegrastim), a new long-acting rhG-CSF therapy for patients with chemotherapy induced neutropenia.
MMIT’s P&T Persectives on Neutropenia reviewed Rolontis® (eflapegrastim), a new long-acting rhG-CSF therapy for patients with chemotherapy induced neutropenia.
MMIT’s P&T Persectives on Neutropenia reviewed Rolontis® (eflapegrastim), a new long-acting rhG-CSF therapy for patients with chemotherapy induced neutropenia.
Syndicated IDN P&T session focused on the entry of two new medications; capmatinib (Tabrecta) from Novartis, and tepotinib from Merck. Indicated for the treatment of adult patients with METex14 skipping mutation NSCLC.
P&T Session NSCLC: Syndicated IDN P&T session focused on the entry of two new medications; capmatinib (Tabrecta) from Novartis, and tepotinib from Merck. Indicated for the treatment of adult patients with METex14 skipping mutation NSCLC.
P&T Session NSCLC: Syndicated IDN P&T session focused on the entry of two new medications; capmatinib (Tabrecta) from Novartis, and tepotinib from Merck. Indicated for the treatment of adult patients with METex14 skipping mutation NSCLC.
P&T Session NSCLC: Syndicated IDN P&T session focused on the entry of two new medications; capmatinib (Tabrecta) from Novartis, and tepotinib from Merck. Indicated for the treatment of adult patients with METex14 skipping mutation NSCLC.
P&T Session NSCLC: Syndicated IDN P&T session focused on the entry of two new medications; capmatinib (Tabrecta) from Novartis, and tepotinib from Merck. Indicated for the treatment of adult patients with METex14 skipping mutation NSCLC.
MMIT recently conducted a syndicated simulated P&T Heart Failure session focused on the entry Farxiga, and anticipated entry of Jardiance, into heart failure.
P&T Session Heart Failure: MMIT recently conducted a syndicated simulated P&T Heart Failure session focused on the entry Farxiga, and anticipated entry of Jardiance, into heart failure.
P&T Session Heart Failure: MMIT recently conducted a syndicated simulated P&T Heart Failure session focused on the entry Farxiga, and anticipated entry of Jardiance, into heart failure.
P&T Session Heart Failure: MMIT recently conducted a syndicated simulated P&T Heart Failure session focused on the entry Farxiga, and anticipated entry of Jardiance, into heart failure.
P&T Session Heart Failure: MMIT recently conducted a syndicated simulated P&T Heart Failure session focused on the entry Farxiga, and anticipated entry of Jardiance, into heart failure.
Description